268 related articles for article (PubMed ID: 32505558)
21. Prophylactic irradiation to the contralateral breast for BRCA mutation carriers with early-stage breast cancer.
Evron E; Ben-David AM; Goldberg H; Fried G; Kaufman B; Catane R; Pfeffer MR; Geffen DB; Chernobelsky P; Karni T; Abdah-Bortnyak R; Rosengarten O; Matceyevsky D; Inbar M; Kuten A; Corn BW
Ann Oncol; 2019 Mar; 30(3):412-417. PubMed ID: 30475942
[TBL] [Abstract][Full Text] [Related]
22. Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers in a large cohort of unselected Chinese breast cancer patients.
Su L; Xu Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
Int J Cancer; 2020 Jun; 146(12):3335-3342. PubMed ID: 32037537
[TBL] [Abstract][Full Text] [Related]
23. Is the breast-conserving treatment with radiotherapy appropriate in BRCA1/2 mutation carriers? Long-term results and review of the literature.
Kirova YM; Savignoni A; Sigal-Zafrani B; de La Rochefordiere A; Salmon RJ; This P; Asselain B; Stoppa-Lyonnet D; Fourquet A
Breast Cancer Res Treat; 2010 Feb; 120(1):119-26. PubMed ID: 20033769
[TBL] [Abstract][Full Text] [Related]
24. Predictors that influence contralateral prophylactic mastectomy election among women with ductal carcinoma in situ who were evaluated for BRCA genetic testing.
Elsayegh N; Kuerer HM; Lin H; Gutierrez Barrera AM; Jackson M; Muse KI; Litton JK; Albarracin C; Afrough A; Hortobagyi GN; Arun BK
Ann Surg Oncol; 2014 Oct; 21(11):3466-72. PubMed ID: 24796968
[TBL] [Abstract][Full Text] [Related]
25. Contralateral prophylactic mastectomy rate and predictive factors among patients with breast cancer who underwent multigene panel testing for hereditary cancer.
Elsayegh N; Webster RD; Gutierrez Barrera AM; Lin H; Kuerer HM; Litton JK; Bedrosian I; Arun BK
Cancer Med; 2018 Jun; 7(6):2718-2726. PubMed ID: 29733510
[TBL] [Abstract][Full Text] [Related]
26. Oncologic Safety of Nipple-Sparing Mastectomy for Breast Cancer in BRCA Gene Mutation Carriers: Outcomes at 70 Months Median Follow-Up.
Webster AJ; Shanno JN; Santa Cruz HS; Kelly BN; Garstka M; Henriquez A; Specht MC; Gadd MA; Verdial FC; Nguyen A; Oseni TO; Coopey SB; Smith BL
Ann Surg Oncol; 2023 Jun; 30(6):3215-3222. PubMed ID: 36604360
[TBL] [Abstract][Full Text] [Related]
27. Frequency of Contralateral Prophylactic Mastectomy in Breast Cancer Patients with a Negative BRCA1 and BRCA2 Rapid Genetic Test Result.
Metcalfe KA; Eisen A; Poll A; Candib A; McCready D; Cil T; Wright F; Demsky R; Mancuso T; Sun P; Narod SA
Ann Surg Oncol; 2021 Sep; 28(9):4967-4973. PubMed ID: 33761021
[TBL] [Abstract][Full Text] [Related]
28. BRCA1/BRCA2 mutations in Japanese women with ductal carcinoma in situ.
Liu Y; Ide Y; Inuzuka M; Tazawa S; Kanada Y; Matsunaga Y; Kuwayama T; Sawada T; Akashi-Tanaka S; Nakamura S
Mol Genet Genomic Med; 2019 Mar; 7(3):e493. PubMed ID: 30652428
[TBL] [Abstract][Full Text] [Related]
29. Factors affecting the decision of breast cancer patients to undergo contralateral prophylactic mastectomy.
Yi M; Hunt KK; Arun BK; Bedrosian I; Barrera AG; Do KA; Kuerer HM; Babiera GV; Mittendorf EA; Ready K; Litton J; Meric-Bernstam F
Cancer Prev Res (Phila); 2010 Aug; 3(8):1026-34. PubMed ID: 20647335
[TBL] [Abstract][Full Text] [Related]
30. Effectiveness of Prophylactic Surgeries in BRCA1 or BRCA2 Mutation Carriers: A Meta-analysis and Systematic Review.
Li X; You R; Wang X; Liu C; Xu Z; Zhou J; Yu B; Xu T; Cai H; Zou Q
Clin Cancer Res; 2016 Aug; 22(15):3971-81. PubMed ID: 26979395
[TBL] [Abstract][Full Text] [Related]
31. Oophorectomy and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers.
Kotsopoulos J; Lubinski J; Lynch HT; Tung N; Armel S; Senter L; Singer CF; Fruscio R; Couch F; Weitzel JN; Karlan B; Foulkes WD; Moller P; Eisen A; Ainsworth P; Neuhausen SL; Olopade O; Sun P; Gronwald J; Narod SA;
Breast Cancer Res Treat; 2019 Jun; 175(2):443-449. PubMed ID: 30756284
[TBL] [Abstract][Full Text] [Related]
32. Survival Outcomes in Women with Unilateral, Triple-Negative, Breast Cancer Correlated with Contralateral Prophylactic Mastectomy.
Fasano GA; Bayard S; Chen Y; Marti J; Simmons R; Swistel A; Bensenhaver J; Davis M; Newman L
Ann Surg Oncol; 2023 Aug; 30(8):4648-4656. PubMed ID: 36681737
[TBL] [Abstract][Full Text] [Related]
33. International rates of breast reconstruction after prophylactic mastectomy in BRCA1 and BRCA2 mutation carriers.
Semple J; Metcalfe KA; Lynch HT; Kim-Sing C; Senter L; Pal T; Ainsworth P; Lubinski J; Tung N; Eng C; Gilchrist D; Blum J; Neuhausen SL; Singer CF; Ghadirian P; Sun P; Narod SA;
Ann Surg Oncol; 2013 Nov; 20(12):3817-22. PubMed ID: 23740344
[TBL] [Abstract][Full Text] [Related]
34. Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation.
Meijers-Heijboer H; Brekelmans CT; Menke-Pluymers M; Seynaeve C; Baalbergen A; Burger C; Crepin E; van den Ouweland AW; van Geel B; Klijn JG
J Clin Oncol; 2003 May; 21(9):1675-81. PubMed ID: 12721241
[TBL] [Abstract][Full Text] [Related]
35. Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers.
Metcalfe K; Gershman S; Lynch HT; Ghadirian P; Tung N; Kim-Sing C; Olopade OI; Domchek S; McLennan J; Eisen A; Foulkes WD; Rosen B; Sun P; Narod SA
Br J Cancer; 2011 Apr; 104(9):1384-92. PubMed ID: 21487411
[TBL] [Abstract][Full Text] [Related]
36. Assessing the Effect of Lifetime Contralateral Breast Cancer Risk on the Selection of Contralateral Prophylactic Mastectomy for Unilateral Breast Cancer.
Hegde JV; Wang X; Attai DJ; DiNome ML; Kusske A; Hoyt AC; Hurvitz SA; Weidhaas JB; Steinberg ML; McCloskey SA
Clin Breast Cancer; 2018 Apr; 18(2):e205-e218. PubMed ID: 29050918
[TBL] [Abstract][Full Text] [Related]
37. Contralateral Breast Cancer and Ipsilateral Breast Tumor Recurrence in
Yoon KH; Chae S; Kang E; Shin HC; Kim JH; Kim IA; Park SY; Kim SW; Kim EK
J Breast Cancer; 2019 Dec; 22(4):587-598. PubMed ID: 31897332
[TBL] [Abstract][Full Text] [Related]
38. Rate of contralateral prophylactic mastectomy is influenced by preoperative MRI recommendations.
Xia C; Schroeder MC; Weigel RJ; Sugg SL; Thomas A
Ann Surg Oncol; 2014 Dec; 21(13):4133-8. PubMed ID: 24934585
[TBL] [Abstract][Full Text] [Related]
39. Incidence of Occult Breast Cancer in Carriers of BRCA1/2 or Other High-Penetrance Pathogenic Variants Undergoing Prophylactic Mastectomy: When is Sentinel Lymph Node Biopsy Indicated?
Wong SM; Ferroum A; Apostolova C; Alhassan B; Prakash I; Basik M; Boileau JF; Meterissian S; Aleynikova O; Wong N; Foulkes WD
Ann Surg Oncol; 2022 Oct; 29(11):6660-6668. PubMed ID: 35616744
[TBL] [Abstract][Full Text] [Related]
40. Surgical management of breast cancer in BRCA-mutation carriers: a systematic review and meta-analysis.
Valachis A; Nearchou AD; Lind P
Breast Cancer Res Treat; 2014 Apr; 144(3):443-55. PubMed ID: 24567198
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]